Several studies showed that increased frequencies of memory T cells or decreased frequencies of naïve-phenotype CD4+ or CD8+ T cells in the blood were correlated with better outcomes in anti-CTLA4-treated melanoma patients (33–35). The gene discussed is CD4; the disease is melanoma.